Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease

Journal of Laboratory and Clinical Medicine

Volumn 131, Issue 4, 1998, Pages 306-315

  Richardson, D R ^a   Ponka, R ^b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0032055861     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-2143(98)90180-9     Document Type: Review

References (78)

1. Hershko C. Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. Baillière's Clin Haematol 1994;7:965-1000.
2. Martell AE, French-Anderson W, Badman DG, editors. Development of iron chelators for clinical use. New York: Elsevier-North Holland, 1981.
3. Modell B, Berdoukas V. The clinical approach to thalassemia. New York: Grune & Stratton, 1984.
4. Propper RD, Cooper B, Rufo RR, Nienhuis AW, Anderson WF, Bunn HF, et al. Continuous subcutaneous administration of desferrioxamine in patients with iron overload. N Engl J Med 1977;297:418-23.
5. Hoffbrand AV, Gorman A, Laulicht M, Garidi M, Economidou J, Georgipoulou P, et al. Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine. Lancet 1979;1:947-9.
6. Ponka P, Borova J, Neuwirt J, Fuchs O. Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett 1979;97:317-21.
7. Ponka P, Borova J, Neuwirt J, Fuchs O, Necas E. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim Biophys Acta 1979;586:278-97.
8. Olivieri NF for the Toronto Iron Chelation Group. Randomized trial of deferiprone (L1) and deferoxamine (DFO) in thalassemia major [abstract]. Blood 1996;88(suppl I):651a.
9. Olivieri NF for the Toronto Iron Chelation Group. Long-term follow-up of body iron in patients with thalassemia major during therapy with the orally active iron chelator deferiprone (L1)[abstract]. Blood 1996;88(suppl I):1229a.
10. Olivieri NF, Brittenham GM. Iron chelation therapy and the treatment of thalassemia. Blood 1997;89:739-61.
11. Dogherty P, Einarson T, Koren G, Sher G. The effectiveness of deferiprone in thalassemia. Blood 1997;90:894.
12. Florence A, Longueville A, Crichton RR. Oral iron chelators may do more harm than good. In: Proceedings of the Ninth International Conference on Proteins of Iron Transport and Storage, July 9-13, Brisbane, Australia: 1989:P118
13. al Refaie FN, Hershko C, Hoffbrand AV, Kosaryan M, Olivieri NF, Tondury P, et al. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. Br J Haematol 1995;91:224-9.
14. al Refaie FN, Wonke B, Hoffbrand AV. Deferiprone-associated myelotoxicity. Eur J Haematol 1994;53:298-301.
15. Kersten MJ, Lange R, Smeets ME, Vreugdenhil G, Roozendaal KJ, Lameijer W, et al. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. Ann Hematol 1996;73:247-52.
16. Castriota-Scanderbeg A, Sacco M. Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone). Br J Haematol 1997;96:254-5.
17. Kontoghiorghes GJ. The design of orally active iron chelators for the treatment of thalassemia. PhD thesis, University of Essex, British Library Microfilm No. D66194/86, 1982.
18. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron, RG, et al. Iron chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995;332:918-22.
19. Diav-Citrin O, Koren G. Oral iron chelation with deferiprone. Pediatr Clin North Am 1997;44:235-47.
20. Tsafack A, Loyevsky M, Ponka P, Cabantchik ZI. Mode of action of iron(III) chelators as anti-malarials. IV. Potentiation of desferal action by benzoyl and isonicotinoyl hydrazone derivatives. J Lab Clin Med 1996;127:574-82.
21. Schulman HM, Hermes-Lima M, Wang EM, Ponka P. In vitro anti-oxidant properties of the iron chelator pyridoxal isonicotinoyl hydrazone and some of its analogs. Redox Report 1996;1:373-8.
22. Richardson DR, Tran E, Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 1995;86:4295-306.
23. Richardson DR, Milnes K. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents II. The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood 1997;89:3025-38.
24. Richardson DR. The potential of iron chelators as effective antiproliferative agents. Can J Physiol Pharmacol 1997;75:1164-80.
25. Richardson DR. Analogues of pyridoxal isonicotinoyl hydrazone (PIH) as potential iron chelators for the treatment of neoplasia. Leuk Lymphoma (in press).
26. Sah P. Nicotinoyl and isonicotinoyl hydrazones of pyridoxal. J Am Chem Soc 1954;76:300-1.
27. World Health Organization. Community control of hereditary anaemias. Bull WHO 1983;61:63-80.
28. Aruffo A, Murphy TB, Johnson DK, Rose NJ, Shomaker V. Structural studies of Fe(III) and Cu(II) complexes of salicylaldehyde benzoyl hydrazone, a synthetic chelating agent exhibiting diverse biological properties. Inorganica Chim Acta 1982;67:L25-7.
29. Murphy TB, Johnson DK, Rose NJ, Aruffo A, Schomaker V. Structural studies of iron(III) complexes of the new iron-binding drug pyridoxal isonicotinoyl hydrazone. Inorg Chim Acta 1982;66:L67-8.
30. Richardson DR, Wis Vitolo ML, Hefter GT, May PM, Clare BW, Webb J, et al. Iron chelators of the pyridoxal isonicotinoyl hydrazone class part 1. Ionisation characteristics of the ligands and their relevance to biological properties. Inorganica Chim Acta 1990;170:165-70.
31. Baker E, Vitolo ML, Webb JM. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture. Biochem Pharmacol 1985;34:3011-7.
32. Baker E, Richardson DR, Gross S, Ponka P. Evaluation of the iron chelation potential of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology 1992;15:492-501.
33. Richardson DR, Baker E. The release of iron and transferrin from the human melanoma cell. Biochim Biophys Acta 1991;1091:294-302.
34. Schmidt RF, Thews G. Human physiology. New York: Springer-Verlag, 1983.
35. 51Cr-labelled EDTA, L-rhamnose and polyeth-yleneglycol 400 as probe markers for assessment in vivo of human intestinal permeability. Clin Sci 1986;71:71-80.
36. Travis S, Menzies I. Intestinal permeability: functional assessment and significance. Clin Sci 1992;82:471-80.
37. Johnson DK, Pippard MJ, Murphy TB, Rose NJ. An in vivo evaluation of iron chelating drugs derived from pyridoxal and its analogues. J Pharmacol Exp Ther 1982;221:399-403.
38. Martell AE. The design and synthesis of chelating agents. In: Martell AE, French-Anderson W, Badman DG, editors. Development of iron chelators for clinical use. New York: Elsevier-North Holland, 1981:67-104.
39. Avramovici-Grisaru S, Sarel S, Link G, Hershko C. Syntheses of iron bis(pyridoxal isonicotinoyl hydrazone)s and the in vivo iron-removal properties of some pyridoxal derivatives. J Med Chem 1983;26:298-302.
40. Vitolo L. The chemical characterization of analogues of pyridoxal isonicotinoyl hydrazone. PhD thesis, School of Mathematical and Physical Sciences, Murdoch University, Perth, Western Australia, 6150, 1984.
41. Webb J, Vitolo ML. Pyridoxal isonicotinoyl hydrazone (PIH): a promising new iron chelator. Birth Defects 1988;23:63-70.
42. Vitolo LMW, Hefter GT, Clare BW, Webb J. Iron chelators of the pyridoxal isonicotinoyl hydrazone class Part 2. Formation constants with iron(III) and iron(II). Inorg Chim Acta 1990;170:171-4.
43. 59Fe. Biochim Biophys Acta 1983;757:306-15.
44. Richardson DR. Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process. Biochim Biophys Acta 1997;1320:45-57.
45. Ponka P, Schulman HM, Wilczynska A. Ferric pyridoxal isonicotinoyl hydrazone can provide iron for heme synthesis in reticulocytes. Biochim Biophys Acta 1982;718:151-8.
46. Breuer W, Epsztein S, Millgram P, Cabantchik ZI. Transport of iron and other transition metals into cells as revealed by a fluorescent probe. Am J Physiol 1995;268:C1354-61.
47. Breuer W, Epsztein S, Cabantchik ZI. Iron acquired from transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable Fe(II). J Biol Chem 1995;270:24207-15.
48. Richardson DR, Ponka P. The iron metabolism of the human neuroblastoma cell. Lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis. J Lab Clin Med 1994;124:660-71.
49. Crumbliss AL, Palmer RA, Sprinkle KA, Whitcombe D. Development of iron chelators: the Duke program. In: Anderson WF, Hiller MC, editors. Proceedings of a Symposium on the Development of Iron Chelators for Clinical Use. Bethesda, Maryland: DHEW Publication No. (NIH) 77-994, 1975:175-97.
50. Richardson DR, Hefter GT, May PM, Webb, J, Baker E. Iron chelators of the pyridoxal isonicotinoyl hydrazone class III. Formation constants with calcium(II), magnesium(II) and zinc(II). Biol Metals 1989;2:161-7.
51. Cikrt M, Ponka P, Necas E, Neuwirt J. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone. Br J Haematol 1980;45:275-83.
52. Richardson DR, Wis Vitolo L, Baker E, Webb J. Pyridoxal isonicotinoyl hydrazone and analogues. Study of their stability in acidic, neutral and basic aqueous solutions by ultraviolet-visible spectrophotometry. Biol Metals 1989;2:69-76.
53. Goodman LS, Gilman A. The pharmacological basis of therapeutics. London: Macmillan, 1980.
54. Williams A, Hoy T, Pugh A, Jacobs A. Pyridoxal complexes as potential chelating agents for oral therapy in transfusional iron overload. J Pharm Pharmacol 1982;34:730-2.
55. Ponka P, Wilczynska A, Schulman HM. Iron utilization in rabbit reticulocytes. A study using succinylacetone as an inhibitor of heme synthesis. Biochim Biophys Acta 1982;720:96-105.
56. Adams ML, Ostapiuk I, Grasso JA. The effects of inhibition of heme synthesis on the intracellular localisation of iron in rat reticulocytes. Biochim Biophys Acta 1989;1012:243-53.
57. Richardson DR, Ponka P, Vyoral D. Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: examination of the intermediates of iron metabolism. Blood 1996;87:3477-88.
58. Morgan EH. Chelator-mediated iron efflux from reticulocytes. Biochim Biophys Acta 1983;733:39-50.
59. Hoy T, Humphreys J, Jacobs A, Williams A, Ponka P. Effective iron chelation following oral administration of an isoniazid-pyridoxal hydrazone. Br J Haematol 1979;43:443-9.
60. Hershko C, Avramovici-Grisaru S, Link G, Gelfand L, Sarel S. Mechanisms of in vivo chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal. J Lab Clin Med 1981;98:99-108.
61. Kim BK, Huebers HA, Finch CA. Effectiveness of oral iron chelators assayed in the rat. Am J Hematol 1987;24:277-84.
62. Sharma BK, Tavill AS, Louis LN, Wiesen E, Varnes AW. Enterai pyridoxal isonicotinoyl hydrazone (PIH) is an effective chelator in experimental iron overload by promotion of biliary iron excretion [abstract]. Hepatology 1989;10:573.
63. Sookvanichsilp N, Nakornchai S, Weerapradist W. Toxicological study of pyridoxal isonicotinoyl hydrazone: acute and subchronic toxicity. Drug Chem Toxicol 1991;14:395-403.
64. Fredenburg AM, Sethi RK, Allen DD, Yokel RA. The pharmacokinetics and blood brain barrier permeation of the chelators 1,2 dimethyl-, 1,2 diethyl-, and 1-[ethan-1′ ol]-2-methyl-3-hydroxypyridin-4-one in the rat. Toxicology 1996;108:191-9.
65. Crowe A, Morgan EH. Effects of chelators on iron uptake and release by the brain in the rat. Neurochem Res 1994;19:71-6.
66. Brittenham GM. Pyridoxal isonicotinoyl hydrazone: an effective iron-chelator after oral administration. Semin Hematol 1990;27:112-6.
67. Hider RC, Kontoghiorghes GJ, Silver J. UK Patent: GB-2118176, 1982.
68. Cerami A. The future of new iron chelating drugs. In: Martell AE, Anderson WF, Badman DG, editors. Development of iron chelators for clinical use. New York: Elsevier North Holland Inc., 1981:197-200.
69. Vitolo L, Webb J, Saltman P. Release of iron from ferritin by pyridoxal isonicotinoyl hydrazone and related compounds. J Inorg Biochem 1984;20:255-62.
70. Ponka P, Richardson D, Baker E, Schulman HM, Edward JT. Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes. Biochim Biophys Acta 1988;967:122-9.
71. Richardson D, Ponka P, Baker E. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res 1994;54:685-9.
72. Bakkeren DL, de Jeu-Jaspars CMH, Kroos MJ, van Eijk HG. Release of iron from endosomes is an early step in the transferrin cycle. Int J Biochem 1987;19:179-86.
73. Richardson D, Baker E, Ponka P, Wilairat P, Vitolo ML, Webb J. Effects of pyridoxal isonicotinoyl hydrazone and analogs on iron metabolism in hepatocytes and macrophages in culture. Birth Defects 1988;23:81-8.
74. Richardson D, Cikrt M, Schulman HM, Baker E, Ponka P. Effect of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1naphthylaldehyde on iron metabolism in hepatocytes and on biliary iron excretion. In: Proceedings of the Third NIH Sponsored Symposium on the Development of Iron Chelators for Clinical Use, May 20-22, Gainesville, Fla., 1992:29.
75. Blaha K, Cikrt M, Nerudova J, Fornuskova H, Ponka P. Biliary iron excretion in rats following treatment with analogues of pyridoxal isonicotinoyl hydrazone [abstract]. Blood (in press).
76. Lea A, Hansch C, Elkins D. Partition coefficients and their uses. Chem Rev 1971;71:525-55.
77. Hider RC. Potential protection from toxicity by oral iron chelators. Toxicol Lett 1995;83:961-7.
78. Martell AE, Smith RM. Critical stability constants (vol 3). New York: Plenum Press, 1977.